Literature DB >> 8556014

Psychometric properties of a specific quality of life questionnaire in angina pectoris patients.

P Marquis1, C Fayol, J E Joire, A Leplège.   

Abstract

This paper describes the psychometric properties of the French version of the APQLQ (Angina Pectoris Quality of Life Questionnaire), that is to say, scaling assumptions, reliability and validity. This disease-specific Swedish questionnaire provides a global score as well as four subscores measuring physical activities, somatic symptoms, emotional distress, and life satisfaction. The French version was produced according to the forward-backward translation methodology. In a cross-sectional study, 183 coronary patients filled out the APQLQ and the MOS (Medical Outcomes Study) SF-36; 170 sent it back; the rate of missing data was low (1.3%). The factorial structure and the high level of inter-scale correlations (> 0.60) suggested that the APQLQ measured one global concept rather than separate domains. The multitrait analysis identified one problematic item correlated strongly with all domains. The internal consistency was good (alpha Cronbach > 0.70). The correlations with the SF-36 scales were consistent with what was expected. The distribution of the scores of the APQLQ according to the clinical severity of Angina Pectoris (AP) was as hypothesized: the more severe the AP, the more impaired the Quality of Life. The score significantly discriminated between symptomatic (n = 110) and asymptomatic patients (n = 60) except for the emotional distress scale (p = 0.14). We recommend to analyze the French APQLQ as an index rather than as a profile. Its reliability, concurrent and clinical validity allowed its use in clinical trials.

Entities:  

Mesh:

Year:  1995        PMID: 8556014     DOI: 10.1007/bf00634749

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  A summary index for the assessment of quality of life in angina pectoris.

Authors:  A Wilson; I Wiklund; T Lahti; M Wahl
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  Functional classification of cardiac disease: a critique.

Authors:  A Selzer; K Cohn
Journal:  Am J Cardiol       Date:  1972-08       Impact factor: 2.778

5.  The relationship between exercise tolerance and quality of life in angina pectoris.

Authors:  I Wiklund; M B Comerford; E Dimenäs
Journal:  Clin Cardiol       Date:  1991-03       Impact factor: 2.882

6.  [Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: the MOS SF-36 (version 1.1)].

Authors:  A Leplège; M Mesbah; P Marquis
Journal:  Rev Epidemiol Sante Publique       Date:  1995       Impact factor: 1.019

7.  Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates.

Authors:  A Nissinen; I Wiklund; T Lahti; J Akkila; A Wilson; M Wahl; P Puska
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

8.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

9.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

10.  Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo.

Authors:  A Fletcher; P McLoone; C Bulpitt
Journal:  Lancet       Date:  1988-07-02       Impact factor: 79.321

View more
  6 in total

1.  Validation of a specific quality of life questionnaire for functional digestive disorders.

Authors:  O Chassany; P Marquis; B Scherrer; N W Read; T Finger; J F Bergmann; B Fraitag; J Geneve; C Caulin
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Life satisfaction in patients with chest pain subsequently diagnosed as coronary heart disease--connection through depressive symptoms?

Authors:  M Valkamo; H T Koivumaa-Honkanen; J Hintikka; L Niskanen; K Honkalampi; H Viinamäki
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

3.  Quality of life in patients with non-CAD chest pain: associations to fear of pain and psychiatric disorder severity.

Authors:  Katherine Hadlandsmyth; Kamila S White; Ronald J Krone
Journal:  J Clin Psychol Med Settings       Date:  2013-09

4.  Maximal exercise electrocardiography responses and coronary heart disease mortality among men with diabetes mellitus.

Authors:  G William Lyerly; Xuemei Sui; Timothy S Church; Carl J Lavie; Gregory A Hand; Steven N Blair
Journal:  Circulation       Date:  2008-05-19       Impact factor: 29.690

5.  The association between cardiorespiratory fitness and risk of all-cause mortality among women with impaired fasting glucose or undiagnosed diabetes mellitus.

Authors:  G William Lyerly; Xuemei Sui; Carl J Lavie; Timothy S Church; Gregory A Hand; Steven N Blair
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

6.  Development and validation of the coronary heart disease scale under the system of quality of life instruments for chronic diseases QLICD-CHD: combinations of classical test theory and Generalizability Theory.

Authors:  Chonghua Wan; Hezhan Li; Xuejin Fan; Ruixue Yang; Jiahua Pan; Wenru Chen; Rong Zhao
Journal:  Health Qual Life Outcomes       Date:  2014-06-04       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.